New IPF drug passes early safety check in small trial
NCT ID NCT03422068
First seen Jan 09, 2026
Summary
This early-stage study tested a new oral drug, BI 1015550, in 15 people with idiopathic pulmonary fibrosis (IPF) who were not taking other IPF medications. The main goal was to see if the drug is safe and tolerable. Researchers also measured how the drug moves through the body. The trial has been completed, but results are not yet publicly available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medisch Centrum
Rotterdam, 3015 CE, Netherlands
-
Fraunhofer ITEM
Hanover, 30625, Germany
-
HYKS Keuhkosairauksien tutkimusyksikkö
Helsinki, 00290, Finland
-
Hospital de Bellvitge
L'Hospitalet de Llobregat, 08907, Spain
-
Odense University Hospital
Odense, 5000 C, Denmark
-
Poli Univ A. Gemelli
Roma, 00168, Italy
-
Royal Brompton Hospital
London, SW3 6NP, United Kingdom
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
St. Antonius ziekenhuis, locatie Nieuwegein
Nieuwegein, 3435 CM, Netherlands
-
TYKS
Turku, 20520, Finland
-
Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.